Azitra, Inc. reported a net loss of $11.0 million for the year ended December 31, 2025, an increase from $9.0 million in 2024. Cash and cash equivalents decreased significantly to $2.1 million as of December 31, 2025, from $4.6 million in 2024. The company initiated a Phase 1/2 trial for its ATR-04 program targeting EGFRi-associated rash in oncology patients, with the first patient dosed in Q3 2025. Positive preclinical data was announced for the ATR-01 program, which targets ichthyosis vulgaris. Promising safety data was reported from the Phase 1b trial of ATR-12 for Netherton Syndrome, with 50% of patients enrolled. Azitra completed financings totaling $8.5 million in 2025 through private placements, follow-on financings, and an equity line of credit. Research and Development (R&D) expenses slightly increased to $4.8 million in 2025 from $4.7 million in 2024. General and Administrative (G&A) expenses slightly decreased to $6.2 million in 2025 from $6.3 million in 2024.